Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Hartsfield Syndrome.

Dhamija R, Babovic-Vuksanovic D.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2016 Mar 3.

2.

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.

de Vries Schultink AH, Suleiman AA, Schellens JH, Beijnen JH, Huitema AD.

Eur J Clin Pharmacol. 2016 Jun;72(6):645-53. doi: 10.1007/s00228-016-2030-4. Epub 2016 Feb 26. Review.

3.

Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors.

Lupu I, Voiculescu VM, Bacalbasa N, Prie BE, Cojocaru I, Giurcaneanu C.

J Med Life. 2015;8 Spec Issue:57-61. Review.

4.

TP63-Related Disorders.

Sutton VR, van Bokhoven H.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2010 Jun 8 [updated 2015 Aug 6].

5.

Timothy Syndrome.

Napolitano C, Splawski I, Timothy KW, Bloise R, Priori SG.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2006 Feb 15 [updated 2015 Jul 16].

6.

Long QT Syndrome.

Alders M, Christiaans I.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
2003 Feb 20 [updated 2015 Jun 18].

7.

Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.

McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E.

Ann Oncol. 2015 Oct;26(10):2017-26. doi: 10.1093/annonc/mdv244. Epub 2015 Jun 1. Review.

8.

Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.

He AB, Peng XL, Song J, Zhang JX, Dong WG, Luo RF, Tang Y.

World J Gastroenterol. 2015 Apr 14;21(14):4358-64. doi: 10.3748/wjg.v21.i14.4358. Review.

9.

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Gunnarsson O, Pfanzelter NR, Cohen RB, Keefe SM.

Cancer Manag Res. 2015 Feb 11;7:65-73. doi: 10.2147/CMAR.S74202. eCollection 2015. Review.

10.

An overview of doxorubicin formulations in cancer therapy.

Rivankar S.

J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8. doi: 10.4103/0973-1482.139267. Review.

11.

Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

Klein Hesselink EN, Steenvoorden D, Kapiteijn E, Corssmit EP, van der Horst-Schrivers AN, Lefrandt JD, Links TP, Dekkers OM.

Eur J Endocrinol. 2015 May;172(5):R215-25. doi: 10.1530/EJE-14-0788. Epub 2015 Jan 8. Review.

12.

A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.

Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME.

Support Care Cancer. 2015 Aug;23(8):2231-44. doi: 10.1007/s00520-014-2564-x. Epub 2015 Jan 7. Review.

13.

Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis.

Asmis T, Berry S, Cosby R, Chan K, Coburn N, Rother M; Cancer Care Ontario’s Gastrointestinal Disease Site Group.

Curr Oncol. 2014 Dec;21(6):318-28. doi: 10.3747/co.21.2146. Review.

14.

Hand, foot, and mouth disease: identifying and managing an acute viral syndrome.

Repass GL, Palmer WC, Stancampiano FF.

Cleve Clin J Med. 2014 Sep;81(9):537-43. doi: 10.3949/ccjm.81a.13132. Review.

15.

Delayed Presentation of DPD Deficiency in Colorectal Cancer.

Law L, Rogers J, Eng C.

J Adv Pract Oncol. 2014 May;5(3):205-10. Review.

16.

Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.

Mokrim M, Aftimos PG, Errihani H, Piccart-Gebhart M.

BMJ Case Rep. 2014 Apr 19;2014. pii: bcr2014203647. doi: 10.1136/bcr-2014-203647. Review.

17.

Sorafenib in metastatic thyroid cancer: a systematic review.

Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME.

Oncologist. 2014 Mar;19(3):251-8. doi: 10.1634/theoncologist.2013-0362. Epub 2014 Feb 21. Review.

18.

Human HOX gene disorders.

Quinonez SC, Innis JW.

Mol Genet Metab. 2014 Jan;111(1):4-15. doi: 10.1016/j.ymgme.2013.10.012. Epub 2013 Oct 29. Review.

19.

Split-hand/foot malformation - molecular cause and implications in genetic counseling.

Sowińska-Seidler A, Socha M, Jamsheer A.

J Appl Genet. 2014 Feb;55(1):105-15. doi: 10.1007/s13353-013-0178-5. Epub 2013 Oct 27. Review.

20.

Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.

Chen M, Zhang L, Wang Q, Shen J.

PLoS One. 2013 Aug 20;8(8):e72245. doi: 10.1371/journal.pone.0072245. eCollection 2013. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk